Castle Biosciences Inc. (CSTL) Tops Q3 EPS by 35c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. SPY
10. FISV

Go back to Castle Biosciences Inc. (CSTL) Tops Q3 EPS by 35c, Revenues Beat

Castle Biosciences Reports Third Quarter 2019 Results

November 11, 2019 4:05 PM EST

Q3 2019 DecisionDx-Melanoma test report volume increased 32% compared to Q3 2018
Q3 2019 recognized revenues increased to $14.8 million, up from $3.7 million in Q3 2018
Q3 2019 gross margin increased to 88%, up from 64% in Q3 2018
December 2019 salesforce expansion
Presented clinical validation data for DecisionDx-SCC
Conference call and webcast today at 4:30 p.m. ET

FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced its financial results for... More